Kornimate/medical-research-clean huggingface dataset:
a short treatment study of aripiprazole in pediatric patients with schizophrenia

Conditions: Schizophrenia

Summary: the objective of this study is to investigate the efficacy and safety of three different doses of aripiprazole (2 mg/day, 6-12 mg/day, 24-30 mg/day) orally administered over a period of 6 weeks in pediatric patients (aged 13-17 years) with schizophrenia


Eligibility criteria:
inclusion criteria: * patients with a diagnosis of schizophrenia (295.30, 295.10, 295.20, 295.90, 295.60), according to dsm-ⅳ-tr (m.i.n.i.kid will be used as backup) * male and female patients aged 13-17 years (between ic and end of dosing) * patients with a panss score of 70 or more \[both at start of dosing (day 1 and at baseline * patients who, in addition to their legal guardian, provide written informed consent, having understood the details of this study * inpatient or outpatient status exclusion criteria: * patients who have a diagnosis of any other disease except schizophrenia, according to dsm-iv-tr * patients who have been compulsorily admitted to hospital * patients with mental retardation * patients with thyroid disorder * patients who have a history of receiving treatment with clozapine, or who have received sufficient doses of two or more kinds of antipsychotic drug for more than four weeks but failed to respond to this treatment * patients who have received a prohibited concomitant medication or therapy listed in table 6.4-1 after the start of the prohibited concomitant medication timeframe \[to be confirmed at start of dosing (day 1) and at baseline\]. * patients who have a history of receiving treatment with aripiprazole * patients who fall under a contraindication listed in the abilify package insert * patients with a serious hepatic, renal, cardiac or hematopoietic disorder * patients with a history or a complication of organic brain disorder or convulsive disorder such as epilepsy * patients with diabetes. and patients who fall under any of the following: fasting blood glucose level ≧126 mg/ｄl, non-fasting blood glucose level ≧200 mg/dl, hba1c≧6.5% * patients with a history or a complication of suicide attempt, suicidal thought or self-harm * patients with a score of ≧2(mild) on part1 evaluation of cgi-ss * patients with a history or a complication of malignant syndrome, tardive dyskinesia or paralytic ileus * patients in a state of physical exhaustion accompanied by such conditions as dehydration or malnutrition * patients with a history or a complication of water intoxication * patients with parkinson's disease * pregnant women, parturient women, nursing women, women of childbearing potential who wish to become pregnant during this trial. however, women of childbearing potential who are practicing an appropriate method of contraception and have a negative pregnancy test result are eligible for inclusion in this study. * patients who have a diagnosis of a substance-related disorder according to dsm-ⅳ-tr within the past 3 months * patients with a positive drug screen (urine) result * study enrollment is otherwise judged to be inappropriate by the investigator or subinvestigator

Keywords: schyzophrenia, pediatric patients
clinical trial to evaluate the safety and effectiveness of a canaloplasty device in subjects with open-angle glaucoma

Conditions: POAG

Summary: clinical trial to evaluate the safety and effectiveness of a canaloplasty device in subjects with open-angle glaucoma


Eligibility criteria:
inclusion criteria: 1. subjects qualifying for cataract surgery 2. subjects with diagnosis of open-angle glaucoma in at least one eye with unmedicated iop of 22-34 mmhg. exclusion criteria: 1. patients who cannot be washed-out of iop-lowering medications.
evaluation of diode laser and topical steroid therapy in the treatment of erosive oral lichen planus

Conditions: Erosive Oral Lichen Planus

Summary: this study evaluates the effect of diode laser in treatment of oral lichen planus.

44 patients with erosive oral lichen planus were included in the study and divided into 2 equal groups. group i received topical steroid therapy three times daily for 4 weeks and antifungal oral gel once daily for 1 week. group ii received 980nm diode laser 300 mw, up to 10 sessions.

Eligibility criteria:
inclusion criteria: * patient histologically diagnosed with erosive olp based on who modified criteria 2003. * presence of painful erosive olp lesions diagnosed by biopsy exclusion criteria: * pregnant or breast-feeding women * patients currently treated for cancer with chemotherapy or radiotherapy * patient currently on corticosteroid therapy or had this treatment on the past 3 months * those who had used anti-inflammatory drugs topical or systemic in the last month * the use of drugs related to oral lichenoid lesions * presence of amalgam restorations near the olp lesions * dysplasia in histopathological examination * uncontrolled systemic diseases * physical or mental abnormality which would interfere with or be affected by the study procedure * patients with skin lesion
effect of screen time exposure on eating behaviour and health related quality of life

Conditions: Eating Behavior Disorders; Health-Related Quality of Life; Screen Time Exposure

Summary: the goal of this observational study is to learn the effect of screen time exposure on eating behaviour and health related quality of life in normal preschool children.

screen media devices have become an integral to daily life, especially for preschool children due to emerging technologies, increased marketing , widespread familial and societal use , and easy access to or ownership for young children. common screen activities include watching television, digital video discs and videos, playing video games, and using apps . however ,excessive screen time, non-educational screen content, unsupervised and early screen exposure can have numerous potential negative effects on children's health . screen time can significantly affect quality of life in various ways, both positively and negatively. regarding cognitive development, screens have the potential to enhance education and learning. however, studies have shown that excessive screen time can negatively affect executive functioning, sensorimotor development, and academic outcomes. early screen exposure has been associated with lower cognitive abilities and academic performance in later years. language development is also affected by screen time, as it diminishes the quantity and quality of interactions between children and caregivers. excessive screen usage can also lead to problems in social-emotional development, including obesity, sleep disturbances, depression, and anxiety. it can impair emotional comprehension, promote aggressive behavior, and hinder social and emotional competence .

Eligibility criteria:
inclusion criteria 1. chronological age range 5 :6 2. both genders will be included 3. according to score of screen dependency scale children stratified into two groups: * group a children score more than 24.5 * group b children score less than 24.5 exclusion criteria:any children has one or more from the following criteria: 1. any surgical intervention in mouth. 2. any congenital anomaly in the mouth as cleft lips or cleft palate. 3. oral disorders
adpkd patient registry

Conditions: Polycystic Kidney Diseases

Summary: the purpose of the adpkd registry is to create an online patient network that includes at least 5,000 people with autosomal dominant polycystic kidney disease (adpkd) who contribute data on their health and other topics. the adpkd patient registry aims to support important scientific discoveries and support patient needs in the following ways: * connect adpkd patients with opportunities to join clinical studies. * collect data for the research community to better describe the adpkd disease experience and improve patient care. * engage with patients by measuring quality of life outcomes.

the adpkd registry will be a patient-powered network of people with adpkd. this data will inform new research to improve adpkd patient outcomes, learn more about the patient journey and discover unmet medical needs. we collect data most relevant to your adpkd diagnosis, its major symptoms and management, as well as key demographic data (no personally identifiable information is shared). a registry keeps information in one place making it easier for researchers to utilize registry information while still protecting the privacy of those who take part. the registry will be hosted on a secure, online platform that patients can access using their home computers, tablets or phones. the purpose of the adpkd registry is to allow pkd patients to: * connect with researchers and express interest in taking part in certain clinical studies for adpkd, including studies of new medications and other treatments. * take confidential health-related surveys. these surveys are aimed at better understanding of the health of people with pkd across their lifespans.

Eligibility criteria:
inclusion criteria: * diagnosis or suspected diagnosis with autosomal dominant polycystic kidney disease (adpkd) exclusion criteria: * caretakers, family members or friends of individuals with adpkd
monitoring anticoagulant therapy in antiphospholipid syndrome

Conditions: Antiphospholipid Syndrome

Summary: to assess the influence of antiphospholipid antibodies on inr test results in patients with the antiphospholipid syndrome anticoagulated with vitamin-k antagonists.

patients with an antiphospholipid syndrome receiving vitamin-k antagonists for secondary prevention after a first thrombotic complication are known to be at higher risk of recurrent thrombotic events despite inr values in the therapeutic range. it ist also known that antiphospholipid antibodies can interfere with phospholipid-dependent tests (e.g. prothrombin time and inr). the primary objective of this study is to determine the prevalence of interfering antiphospholipid antibodies. the intensity of anticoagulant therapy was assessed by measuring the inr using different thromboplastins and the coaguchek system for inr self-assessment. test results were compared to measurements of the phospholipid-independent chromogenic factor x. the second objective of this study is to evaluate the incidence of recurrent thrombotic events during 1-year follow-up.

Eligibility criteria:
inclusion criteria: * age 18-90 years exclusion criteria: * none

Keywords: antiphospholipid syndrome antiphospholipid antibodies vitamin-k antagonists international normalized ratio chromogenic factor x
antibiotics in chronic obstructive pulmonary disease (copd)

Conditions: Pulmonary Disease, Chronic Obstructive

Summary: it is not clear whether antibiotic therapy is needed in patients with mild to moderate exacerbation of chronic obstructive lung disease. the aim of the study is to compare the effect of 1 day of treatment with 6 days of treatment in patients who are admitted to hospital and being clinical stable (as judged by their physician) 24 hours after hospitalization


Eligibility criteria:
inclusion criteria: * age above 50 years * history of smoking * history of copd * antibiotics for 24 hours * at least 2 of the following: dyspnoea, coughing with sputum, and sputum with purulence * informed consent exclusion criteria: * pneumonia * antibiotics for more than 36 hours * antibiotics for other infection * prednisolone, more than 0.5 mg/kg body weight/24 hours for more than 3 days * malignancy * other pulmonary disease * immune deficiency * not able to tolerate doxycycline * severe heart, liver or kidney disease * epilepsia * not stable 24 hours after hospital admission * need for assisted ventilation

Keywords: chronic obstructive pulmonary disease infection antibiotics
evaluation of the prevalence and risk factors for patients with peri-implant disease

Conditions: Jaw, Edentulous, Partially

Summary: to investigate the prevalence and risk factors for peri-implant disease in partially edentulous patients rehabilitated with implants supported crown or bridge so as to provide evidence for clinical prevention and control.

the aim of the present study is to identify the prevalence of peri-implant disease in partially edentulous subjects treated with osseointegrated implants, using clinical parameters, as well as to analyse the possible disease association with demographic, behavioural, and biological risk variables.

Eligibility criteria:
inclusion criteria: * partially edentulous patients will implant at least one implant and will be restored with implant-supported fixed partial dentures and single crowns. exclusion criteria: * jaw radiotherapy treatment before and after implanting. patients who have bruxism,xerostomia or the adjacent teeth periapical periodontitis. * patients who suffered with oral mucosa disease,or aggressive periodontitis or jaw defect. * patients who suffered with mental and psychological disease will influence their oral health normal maintenance.

Keywords: peri-implant disease risk factors prevalence
erinacine a-enriched hericium erinaceus mycelia for improvement of recognition, vision, and functional mri alterations

Conditions: Supplement; Cognition Disorders in Old Age; Vision; fMRI

Summary: this study was designed as randomized double blind placebo study to investigate the efficacy of erinacine a-enriched hericium erinaceus mycelia for improvement of recognition, vision, and functional mri alterations.

patients were recruited with diagnosis of mild or medium dementia, according to criteria by nincds-adrda (national institute of neurological and communicative disorders and stroke-alzheimer's disease and related disorders association) as probable or possible alzheimer's disease. upon signature of informed consent, they were subject to: (1) cognitive assessments, including mini-mental state examination(mmse), neuropsychiatric inventory (npi), cognitive abilities screening instrument (casi), and instrumental activities of daily living (iadl) on weeks 0, 12, 24, and 49, (2) blood markers tests, including dheas, alpha 1-antichymotrypsin, superoxide dismutase, and homocysteine, apolipoprotein e, hemoglobin, calcium, albumin, and amyloid beta on weeks 0, 24, and 49, (3) fmri assessments for super-resolution track density imaging (tdi), and blood oxygenation level-dependent (bold) signal mapping, on weeks 0 and 49, (4) vision assessments, including visual acuity (va) and contrast sensitivity (cs), on weeks 0, 24, and 49. mann-whitney u test and wilcoxon tests were applied to examine the data before and after dietary intake of erinacine a-enriched hericium erinaceus mycelia after 49 weeks.

Eligibility criteria:
inclusion criteria: * aged between 50 and 90 * confirmed diagnosis of mild and intermediate alzheimer's disease based on clinical assessments according to criteria of nincds-adrda (national institute of neurological and communicative disorders and stroke-alzheimer's disease and related disorders association) exclusion criteria: * vulnerable to injuries * loss of self-recognition, * loss of behavioral capacity * with critical illness * with major diseases

Keywords: erinacine a, supplement, alzheimer's disease
stromal tumor-infiltrating lymphocyte levels are associated with immune checkpoint proteins in triple negative breast cancer patients receiving neoadjuvant chemotherapy

Conditions: Triple Negative Breast Cancer

Summary: the goal of this observational study is to learn about the effects of neoadjuvant chemotherapy (nact) anthracycline-containing, taxane- (intervention a +t) and anthracycline/taxane /carboplatin (intervention a+t+c) treatment in young (age; 24-45 years) triple negative breast cancer (tnbc) female patients by evaluating stromal tumor-infiltrating lymphocytes (tils) programmed cell death-1 (pd-1), its ligand (pd-l1) and lymphocyte activation gene-3 (lag-3) checkpoint proteins within tumor. the main question it aims to answer is: does tils are the most reliable immune markers and are significantly associated with pd-1, pd-l1 and lag-3 in carboplatin based nact treated (intervention a+t+c) group of tnbc patients? participants (tnbc patients) already taking intervention a+t and a+t+c as part of their regular medical care for tnbc.

stromal tumor-infiltrating lymphocytes (tils) are currently being considered as a prognostic factor in triple-negative breast cancer (tnbc) and their association with the tumor immune microenvironment is less clear. to address this knowledge gap, investigators aimed to evaluate the expression and association of programmed cell death-1 (pd-1), its ligand (pd-l1) and lymphocyte activation gene-3 (lag-3) checkpoint proteins with tils in neoadjuvant chemotherapy (nact) treated tnbc patients. patients (n=54; aged;24-45 years) were classified into two groups: thirty-nine received anthracycline-containing, taxane- (a+t group) and fifteen received anthracycline/taxane /carboplatin (a+t+c group) in combinations. immunohistochemistry (ihc) staining was used for the evaluation of pd-1, pd-l1 and lag-3. however, til assessment was done by hematoxylin and eosin (h\&e)-staining in tnbc patient's biopsies who received nact.

Eligibility criteria:
inclusion criteria: * female (aged 24-45 years) tnbc patients * diagnosed tnbc patients with immunohistochemistry (ihc) negative test for estrogen receptor (er), progesterone receptor (pr), and her-2 * patients with and without metastases exclusion criteria: * patients who had a history of other malignant tumors * patients who did not complete nac.

Keywords: carboplatin-based nact regimen tumor-infiltrating lymphocytes programmed cell death-1 programmed cell death ligand-1 lymphocyte activation gene-3 triple-negative breast cancer
study to compare on-demand treatment to a prophylaxis regimen of benefix in subjects with moderately severe to severe hemophilia b

Conditions: Hemophilia B

Summary: the purpose of this study will be to determine if a once-weekly prophylaxis regimen of benefix in subjects with moderately severe to severe hemophilia b is safe and effective.


Eligibility criteria:
inclusion criteria: * documented history of moderately-severe to severe hemophilia b (fix activity \</=2%). * male subjects, aged 12 years to 65 years. * subjects with at least 100 exposure days (eds) to factor ix products. * subjects with a minimum of 12 bleeding episodes, 6 of which must be joint bleeds, in the 12-month period before the screening visit. exclusion criteria: * subjects who have received fix as a primary or secondary prophylaxis regimen within the last 12 months prior to the screening visit. * subjects who have had major surgery or an orthopedic surgical procedure within the past 3 months prior to screening visit. * subjects for which major surgery or orthopedic surgery is planned within the duration of study participation. * subjects with a past history of, or current fix inhibitor, defined as \>uln (upper limit of normal) of the reporting laboratory. * subjects with a known hypersensitivity to any fix product or hamster protein.

Keywords: hemophilia b on-demand prophylaxis nonacog alfa benefix fix
clinical performance of habitual hydrogel vs. silicone hydrogel toric contact lenses

Conditions: Astigmatism

Summary: evaluate the clinical performance of existing wearers of hydrogel toric lenses when refitted with avaira toric silicone hydrogel contact lenses over 1 week of wear.

this is a 60-subject, single masked, bilateral, parallel study design comparing the fitting characteristics of enfilcon a toric lenses against the subjects habitual hydrogel toric lenses (omafilcon a, ocufilcon d or methafilcon b wearers). subject's habitual toric lenses will be evaluated at the first visit and then re-fitted with a pair of avaira toric lenses. after 1 week of daily wear, subjects will return for a second and final evaluation.

Eligibility criteria:
inclusion criteria: * is between 18 and 40 years of age (inclusive) * has had a self-reported visual exam in the last two years * is an adapted soft toric contact lens wearer * has a contact lens spherical prescription between +6.00 to - 8.00 (inclusive) * have no less than 0.75d of astigmatism and no more than 1.75 d in both eyes. * can achieve best corrected spectacle distance visual acuity of 20/25 (0.10 logmar) or better in each eye. * can achieve a distance visual acuity of 20/30 (0.18 logmar) or better in each eye with the study contact lenses. * has clear corneas and no active ocular disease * has read, understood and signed the information consent letter. * patient contact lens refraction should fit within the available parameters of the study lenses. * is willing to comply with the wear schedule (at least 5 days per week, \> 8 hours/day assuming there are no contraindications for doing so). * is willing to comply with the visit schedule exclusion criteria: * has a contact lens prescription outside the range of the available parameters of the study lenses. * has a spectacle cylinder less than -0.75d or more than -1.75d of cylinder in either eye. * has a history of not achieving comfortable contact lens wear (5 days per week; \> 8 hours/day) * has contact lens best corrected distance vision worse than 20/25 (0.10 logmar) in either eye. * presence of clinically significant (grade 2-4) anterior segment abnormalities * presence of ocular or systemic disease or need of medications which might interfere with contact lens wear. * slit lamp findings that would contraindicate contact lens wear such as: * pathological dry eye or associated findings * pterygium, pinguecula, or corneal scars within the visual axis * neovascularization \> 0.75 mm in from of the limbus * giant papillary conjunctivitis (gcp) worse than grade 1 * anterior uveitis or iritis (past or present) * seborrheic eczema, seborrheic conjunctivitis * history of corneal ulcers or fungal infections * poor personal hygiene * has a known history of corneal hypoesthesia (reduced corneal sensitivity) * has aphakia, keratoconus or a highly irregular cornea. * has presbyopia or has dependence on spectacles for near work over the contact lenses. * has undergone corneal refractive surgery. * is participating in any other type of eye related clinical or research study.